AbCellera Biologics Inc

ABCL

Company Profile

  • Business description

    AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

  • Contact

    150 W 4th Avenue
    VancouverBCV5Y 1G6
    CAN

    T: +1 604 559-9005

    E: [email protected]

    https://www.abcellera.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    596

Stocks News & Analysis

stocks

Meta earnings: Strong end to 2025 as AI monetization begins to show

Investors please with latest results.
stocks

Why doesn’t the market like the earnings from this US tech giant?

Good quarter with AI demand ramping.
stocks

Our Tesla fair value increases meaningfully

Progress on Robotaxi and Optimus shows real world AI growth.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,236.906.40-0.07%
CAC 408,071.364.680.06%
DAX 4024,309.46513.33-2.07%
Dow JONES (US)49,071.5655.960.11%
FTSE 10010,171.7617.330.17%
HKSE27,968.09141.180.51%
NASDAQ23,685.12172.33-0.72%
Nikkei 22553,375.6016.890.03%
NZX 50 Index13,334.3714.24-0.11%
S&P 5006,969.019.02-0.13%
S&P/ASX 2008,927.504.300.05%
SSE Composite Index4,157.986.750.16%

Market Movers